Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomized, Open-Label, Crossover-Design, Single-Dose Study to Investigate the Safety, Tolerability and Comparative Bioavailability of Oral Edaravone Administered Orally and Via a Nasogastric Tube (NGT) in Healthy Adult Subjects

Next Previous
Trial Profile

A Phase I, Randomized, Open-Label, Crossover-Design, Single-Dose Study to Investigate the Safety, Tolerability and Comparative Bioavailability of Oral Edaravone Administered Orally and Via a Nasogastric Tube (NGT) in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edaravone (Primary) ; Edaravone (Primary)
  • Indications Amyotrophic lateral sclerosis; Cerebral infarction; Liver disorders; Stroke
  • Focus Pharmacokinetics
  • Sponsors Mitsubishi Tanabe Pharma Corporation

Most Recent Events

  • 31 Oct 2025 According to a Tanabe Pharma Corporation media release, Mitsubishi Tanabe Pharma Corporation is now called Tanabe Pharma Corporation.
  • 11 Mar 2022 According to a Mitsubishi Tanabe Pharma America media release, data from this study will be presented at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
  • 01 Dec 2021 According to a Mitsubishi Tanabe Pharma America media release, the trial design will be presented by Antoinette Harrisonat as poster presentation at the Motor Neurone Disease Association (MNDA) 32nd International Symposium on ALS/MND, being held virtually in December, 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top